Replies to post #174306 on Biotech Values

[DewDiligence]

ESRX says it can grow annual EPS 10-20% indefinitely:

http://finance.yahoo.com/news/express-scripts-sees-long-term-224226463.html

"Based on assumptions regarding healthcare trends, industry positioning and the overall environment, the company is targeting annual earnings per share growth of 10 per cent to 20 per cent for the next several years," St Louis-based Express said in a release announcing its quarterly results.

I’m skeptical.